Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
Rodabe N. Amaria(The University of Texas MD Anderson Cancer Center), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Marie‐Andrée Forget(The University of Texas MD Anderson Cancer Center), Mara B. Antonoff(The University of Texas MD Anderson Cancer Center), Ying Yuan(The University of Texas MD Anderson Cancer Center), Patrick Hwu(Moffitt Cancer Center), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Donastas Sakellariou-Thompson(The University of Texas MD Anderson Cancer Center), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Chantale Bernatchez(BMC Software (United States)), David Vining(The University of Texas MD Anderson Cancer Center), Milind Javle(The University of Texas MD Anderson Cancer Center), Anne Knisely(The University of Texas MD Anderson Cancer Center), Ching‐Wei D. Tzeng(The University of Texas MD Anderson Cancer Center), Karen H. Lu(The University of Texas MD Anderson Cancer Center), Bryan Fellman(The University of Texas MD Anderson Cancer Center), Kathryn Lito(The University of Texas MD Anderson Cancer Center), Shubham Pant(The University of Texas MD Anderson Cancer Center), Kelly Rangel(The University of Texas MD Anderson Cancer Center), Michael J. Overman(The University of Texas MD Anderson Cancer Center)
Cited by 54
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k